Ultrasound treatment for heart amyloidosis
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial studies whether ultrasound therapy can help people with amyloidosis that affects the heart. It’s aimed at improving heart-related outcomes in AL or transthyretin (ATTR) cardiac amyloidosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult: over 18 for AL amyloidosis, or over 65 for ATTR amyloidosis (or control group).
- You have confirmed amyloidosis involving the heart, based on approved test results (blood/biopsy plus heart-specific findings).
- Your heart tests are abnormal in a way the study is looking for (blood “cardiac markers,” echocardiogram thickness, or heart MRI findings).
- You can give informed consent and are medically stable enough to complete the treatment visits.
- You can safely lie flat for about 1 hour during the study (not decompensated heart failure).
- You do not have key exclusions like severe lung disease, major valve problems, severe pulmonary pressure problems, or prior heart surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses heart imaging to track disease progression in people with ATTR cardiac amyloidosis who are about to start tafamidis treatment. It aims to understand how the disease changes over time.
This trial studies whether a structured exercise training program is safe and helpful for people with transthyretin (ATTR) cardiac amyloidosis. It may help improve fitness and daily functioning, and it may also compare groups for specific eligibility needs.
This study tests a new PET imaging agent (evuzamitide) to see if it can better detect cardiac amyloidosis when earlier tests were unclear. It may help confirm if the heart problem is related to TTR amyloid and guide further care.
This trial tests a 5-week cardiac rehabilitation program for people with cardiac amyloidosis (a condition where abnormal protein builds up in the heart). The program aims to improve heart function and quality of life.
This study looks at how a type of heart condition called transthyretin cardiac amyloidosis changes over time, using a special imaging test called a bone scan. The goal is to see if the scan can help track the disease and potentially improve care.
This study looks at how cardiac amyloidosis shows up on heart imaging, especially ultrasound (echocardiography). It may help doctors better describe and track the condition using your exam and test results.
Hear when a new Amyloidosis Cardiac trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.